NPHLA Intelligence
Topic intelligence
Every topic NPHLA tracks, organised by desk. Each hub gathers briefings, official records, trials and deadlines in one place — and members can follow the ones that matter to them.
01 Metabolic & Weight-Loss Intelligence
Desk front page- SemaglutideSemaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and marketed under brand names including Ozempic, Wegovy and Rybelsus f…High attention
- TirzepatideTirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro and Zepbound for different indications.Building
- RetatrutideRetatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors developed by Eli Lilly. Its clinical-trial progress and regulato…Building
- LiraglutideLiraglutide is a GLP-1 receptor agonist marketed under brand names including Victoza and Saxenda.Emerging
- OrforglipronOrforglipron is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Its trials and regulatory status are…Emerging
- Oral GLP-1 therapiesGLP-1 therapies taken by mouth rather than by injection — oral peptide formulations and small-molecule GLP-1 receptor agonists.Emerging
- Amylin-based therapiesAmylin analogues and amylin-receptor agonists, such as cagrilintide, studied alone and in combination with GLP-1 therapies for weight man…Building
- Obesity drug pipelineInvestigational obesity and metabolic medicines in clinical development — multi-agonists, amylin combinations, muscle-preserving agents a…Building
- Weight-loss maintenance & regainResearch and practice on maintaining weight loss, and on weight regain after GLP-1 therapy is reduced or stopped.Emerging
- Lean mass & body compositionHow weight-loss therapies affect lean mass, muscle and body composition, and the strategies studied to preserve muscle during weight redu…Emerging
- GLP-1 pricing, coverage & accessPricing, insurance and public-program coverage, employer benefits and direct-to-consumer access for GLP-1 and obesity medicines.
- Diabetes developmentsDevelopments in type 2 diabetes care relevant to pharmacy and metabolic practice, including incretin therapies and cardiometabolic outcomes.High attention
02 Pharmacy, Compounding & Regulatory Intelligence
Desk front page- GLP-1 compoundingCompounding of GLP-1 medicines by 503A pharmacies and 503B outsourcing facilities, and the regulatory questions raised when shortages are…Emerging
- 503A compoundingSection 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by state-licensed pharmacies and physicians, generally on th…Emerging
- 503B outsourcing facilitiesSection 503B of the FD&C Act created outsourcing facilities: compounders that register with the FDA, follow current good manufacturing pr…Emerging
- Peptide regulationFDA and state regulatory developments affecting peptides, including which bulk drug substances may be used in compounding.Emerging
- USP compounding standardsUSP general chapters <795>, <797> and <800> set standards for nonsterile and sterile compounding and for handling hazardous drugs.Emerging
- Drug shortagesFDA drug-shortage determinations and their effect on supply, compounding and patient access.Emerging
- FDA enforcement & warning lettersWarning letters, recalls, import alerts and other FDA enforcement actions affecting pharmacies, compounders and related businesses.Emerging
- DSCSA & drug supply chainThe Drug Supply Chain Security Act requires interoperable, electronic tracing of prescription drugs through the U.S. supply chain.
- PBMs & reimbursementPharmacy benefit manager practices, pharmacy reimbursement and related legislation and regulation.Emerging
- Telehealth prescribing & medication deliveryRules affecting prescribing through telemedicine — including controlled substances — and the delivery of medications to patients.Emerging
- Drug advertising & marketing enforcementFDA and FTC requirements for promoting prescription drugs and health products, including enforcement against misleading marketing.
- State boards of pharmacyRules, guidance and actions from state boards of pharmacy and related state regulators.Emerging
03 Aesthetics, Regenerative & Longevity Medicine
Desk front page- NeurotoxinsBotulinum toxin products used in aesthetic and therapeutic medicine, including approvals, labelling and safety communications.
- Dermal fillers & biostimulatorsHyaluronic-acid fillers and biostimulatory injectables such as poly-L-lactic acid and calcium hydroxylapatite.
- Energy-based aesthetic devicesLasers, radiofrequency, microneedling and other energy-based devices, including FDA 510(k) clearances.Emerging
- PDRN & polynucleotidesPolydeoxyribonucleotide (PDRN) and polynucleotide products used in regenerative aesthetics. Their U.S. regulatory status varies by product.Emerging
- ExosomesExtracellular-vesicle (exosome) products promoted for regenerative and aesthetic uses. NPHLA tracks their evidence and regulatory status.Building
- PRP, PDGF & growth factorsPlatelet-rich plasma, platelet-derived growth factor and other growth-factor approaches used in aesthetic and regenerative medicine.Emerging
- Hair restorationMedical and procedural treatments for hair loss, including drug therapies, devices and regenerative approaches.Building
- Hormonal health & BHRTHormone therapy, including compounded bioidentical hormones, testosterone therapy and menopause care.Emerging
- Longevity medicineResearch and services aimed at extending healthspan, from metabolic and cellular-health research to longevity clinics.
- IV therapyIntravenous hydration and vitamin-therapy services, including their regulation and safety.
- Counterfeit & unapproved productsWarnings about counterfeit, unapproved or illegally marketed products used in aesthetic and weight-loss practice.Emerging
- Med-spa regulation & scope of practiceState rules on supervision, delegation and scope of practice for medical spas and aesthetic procedures.Emerging
04 AI, Technology & Practice Growth
Desk front page- AI in healthcareArtificial intelligence across clinical, administrative and pharmacy settings — capabilities, limits, regulation and governance.Building
- AI agents & MCPSoftware agents that carry out multi-step tasks, and the Model Context Protocol (MCP) and other standards that connect them to tools and …
- AI documentation & scribesAmbient-listening and AI tools that draft clinical notes and documentation.
- Pharmacy automation & roboticsDispensing robotics, central fill, automated workflows and other pharmacy-automation technology.
- Healthcare cybersecurityRansomware, breaches and security requirements affecting healthcare organisations.
- HIPAA & health privacyHIPAA and other health-privacy rules, including enforcement and guidance on online tracking technologies.
- Website tracking & privacy litigationLitigation and regulation involving tracking pixels and analytics on healthcare websites.
- Patient communications & voice AIMessaging, voice AI, booking and intake tools that change how practices communicate with patients.Emerging
- Practice growth & operationsCRM, analytics, membership models, reputation and the operational playbooks of modern practices.Emerging
- Telehealth technologyTelehealth platforms and the technology behind virtual care.Emerging